this an Pete, Basta, made us at all team, members our Ford, leadership immediate you, Chief us and Operating like introducing and Chief impact. I'd two became execution Officer; James strategic Kathy, prioritization operational has in for our Officer. a joined and thank our Legal July, and of senior start joining when newest priorities, Kathleen you the to time our Thank by she highest afternoon.
partnering Biogen, the joined healthy strong Both us the are towards President, and Senior Counsel. Chief and Jim, as to He welcome have She business where yesterday lead brings in recently Board. successful balance from most she operations and drug a corporate Corporation clinical to additions team. served on registrations excited we're where most U.S. our past guardianship, recently him Vice of and development both years, Serono, spent at Europe. XX he just Merck
our Phase and our up mutant neck tumors. AACR-NCI-EORTC programs Targets Triple each you on tipifarnib we from HRAS HRAS of to squamous beginning with trial speed week, bring in Therapeutics of carcinomas, ongoing Meeting mutant solid X on Conference Molecular in or and tipifarnib International cell data the Cancer at the Last me Boston. let head in Now, updated reported
We support demonstrate of were AIM-HN to the very activity because treat population. registration-directed a and compelling They tipifarnib results the validate level difficult our of pleased in enrich clinical activity design ongoing a data trial. for patient strongly strategy the our clinical for to
more let However, the before I in detail, discuss recap me data results themselves. quickly the these significance of
date, enrolled response October As XXXX XX the the data efficacy variant were of valuable allele mutant patients the high in objective frequency cut-off partial a achieved for patients evaluable XX, HNSCC confirmed XX of trial, rate were an whom XX XX RUN-HN a with for response efficacy. ongoing XX%. total of of HRAS of
In one response disease experienced patients unconfirmed date. who as was including stabilization, assessment two an of data addition, a confirmatory of cut-off eight the whom awaiting achieved PR,
to tipifarnib, had two therapy therapy. Patients no disease. observed of patients prior their and for X, median prior from lines months with on who progression-free among patients XX therapy, PR last compared was months X.X on their tipifarnib months evaluable median with The patients X.X the to prior a of X.X last months X.X a ranging those of including treated responses survival X stable on achieved with
tipifarnib. Medical data Oncology XX%, and allele survival in HRAS with approximately Conference therapies benefit significant in for approved European clinical HNSCC mutant October presented currently our progression-free frequency a previous of the the the XX% trial the ESMO XXXX, nivolumab months. Recall to range and response treatment line, the second overall the that As of cetuximab from tumor, three association update for reminder, from two at the a from for rate showed RUN-HN between or Society in pembrolizumab,
We also higher XXX cycle analysis at study milligrams retrospective at the patients between doses one end BID, reported dose median revealed milligrams and was on of XXX starting dose, although the patients trial our discontinuations evaluating interruptions BID. of the and XXX for was that the that due to approximately
Based upon introduced these study. changes we into the observations, RUN-HN two
BID directed was variant require to XXXX. Notably, as shortly we starting second, minimum same thereafter allele initiated changes implemented AIM-HN in established First, a an criterion XXX dose. the And for HRAS we our for we trial, mutant entry frequency, which the enrollment. registration the November milligrams protocol as
allele Of high PR, XXXX unconfirmed awaiting of patients, an confirmatory date. initial ESMO pending initial an achieved with response in non-evaluable the five Of prior the response eight is was to year XX confirmed assessment, assessment. achieved including a an as who trial. response one discontinued one whom mutant a the the tumor of evaluable a variant frequency cutoff RUN-HN the two, disease, patients update data three other PR, efficacy we had HRAS the ago, new two patients Since stable prospectively enrolled patients, assessment
to trial, whom are the started We of objective dose, believe dose key takeaways RUN-HN three total from five update. an of XXX RUN-HN all efficacy in achieved regard evaluable patients With milligram there the HNSCC last a response. week's at clinical
activity. around clinical trial than population number and study, reflect sufficient three, more in valuable with effective tolerated patients multi-center requirement that activity to BID be real-world including dose the drive two, world, to clinical HRAS is Number mutant the one, sites a with to allele in starting the Number the in RUN-HN clinical better an a frequency given data enrich durable experience XX mutant the this of patient variant HRAS means run appears And setting. milligram anti-tumor tipifarnib HNSCC. minimum XXX this suggest for
benefit increase view HNSCC the design, registration provide results HNSCC. the and of together, in to of can Meeting AIM-HN, and presented they our of that reinforce tipifarnib tipifarnib directed Taken clinical meaningful outcome, mutations, mutant Triple our our the with in patients, HRAS at confidence success trial probability HRAS further
open The study and designed is received more platinum-based now and at year enroll evaluable prior with high AIM-HN to than patients variant allele HNSCC is have frequency, XX least mutant the Europe, in therapy. who ago sites in was AIM-HN initiated Asia. XX HRAS clinical exactly U.S., one
believe to that study enrollment. will two years take continue for approximately full We AIM-HN the
given design efficacy requirement screen the the of and that when However, the allele since allele confirmed responses minimum primary frequency enrollment. of observed. if Also, HRAS the potential that find we there the variant of mutant that XX met are endpoint to worth could objective introduction the study, the be AIM-HN the noting it's approximately HRAS patients meet of frequency continue X% for is requirement, we
marketing first is package data for in goal programs generate sufficient application a mutant HNSCC. approval HRAS the for to primary tipifarnib Our support to a
and in compelling from we're Triple the pursue demonstrated opportunities population, the activity including with of HRAS mutant therapy, Meeting cetuximab might how with lower However, we signals immune combination population. data, the also chemotherapy, the broader variant evaluating allele for frequency
standard could which Given mutations and commercial mechanism no believe competitors of the to to there today, be direct resistance therapies, role a tipifarnib of we a to is meaningful one XX% population, expanded to XX% potentially opportunity are in HRAS of the HNSCC tipifarnib.
combinations in other for label Although in expansion lines future HRAS groundwork also represent expansion opportunities the we're immediate tumor mutant for to HNSCC believe we indications. tipifarnib, solid of for laying therapy earlier
Medical trial reported HRAS the ongoing of South efficacy urothelial medical of we data are to presented September, Center being tipifarnib an its future Samsung in primary met analysis mutant Korea. X carcinomas is expected enrollment. that in prior conducted in and to a completion Further example, investigator-sponsored trial at the endpoint Seoul, The For Phase trial of be is at meeting.
consist enroll continues X consortium. XXX In lung to tipifarnib They carcinomas squamous oncology in by in and being conducted Spain. cancer cell Phase addition, than of patients. a more an of trial trial public is private investigator-sponsored The centers lung
in in tipifarnib of HRAS showed expand solid first lymphoma high biomarkers lymphoma, In mutant aggressive discovery XXX% a biomarkers pathway CXCLXX with beyond T-cell June, AITL. including the the Meanwhile, heavily for opportunity trial XX% validation well pretreated potential peripheral prospective complete the to and CXCLXX clinical T-cell T-cell patients of enrich in our ongoing of levels subset angioimmunoblastic we X clinical to for Phase a of lymphoma of or tumors. pathway expression. response rate by offers activity often form characterized rate of CXCLXX a benefit An tipifarnib the
concept year, next at European Malignant continue Conference Association Phase in the to earlier Hematology from Congress International authorities gather X the of this feedback support on multiple presented around And data program. leaders this opinion we opportunities relapsed-refractory registrational regulatory believe We PTCL, Lymphoma AITL and lymphoma. key steps proof in and for
continue Clinic Mayo an Hematology in that additional we that and new of at the Given cohort, been thus by Society order including in cohort more from American Thomas this Dr. to patients far pleased regarding have safety the acquire to upcoming AITL high to for of cohort, data, I'm activity Annual the Witzig the population. report AITL oral patient presentation tolerability enroll level clinical the in Meeting December. of experience observed in accepted patients in
on body and Based T-cell we would indications, tumor leukemia, solid for believe we therapeutic of diffuse may CXCLXX believe B-cell the have in farnesyltransferase potential lymphoma, unlock acute our inhibition and Over the enable registrational to solid tumor of biomarkers multiple growing lymphoma, myeloid time, hematologic strategies this including value pathway indications. cancer. hematologic across data, multiple large and cutaneous tipifarnib pancreatic
a advanced and growing mutant patent directed This CXCLXX to relapsed patents any patent, our to to issued support with involving portfolio the of biomarkers, inhibitor. exclusivity of that extending of transferase inhibitor metastatic method any farnesyl In to recently of PTCL the or U.S. the it farnesyltransferase Office AML. development or pathway pleased Patent I'm adds treating tipifarnib, refractory for using of report patients for CXCLXX further Trademark this strategy HRAS treatment of another HNSCC, year, new the use our issuance and a our further expressing follows
advance XXXX, These of patents new possible to property the pursue protection, extension. in our believe term intend patents new advantage continue both and strengthen XXXX to as expire we development in continue excluding intellectual the and abroad. patent these to we aggressively and We tipifarnib U.S. any competitive respectively,
with of patients KO-XXX of selective pipeline as is with a inhibitor a spend advancing the on MAPK our activity each tumors dysregulated KO-XXX. that have ERK we inhibitor which and let's beginning treatment a potent the of are ERK Now, emerging for potential moment programs pathway. small-molecule
BRAF data subsets Our carcinomas. preclinical in as squamous mutant adenocarcinomas, KRAS as that certain has activity or well suggest of KO-XXX cell anti-tumor
frequent more schedule schedule a including of this X the next We continue year. of for reaching or recommended goal once-weekly dosing to dosing end tolerated a early evaluate a dose with maximum dose intermittent or KO-XXX, year regimens by and Phase a
data presented Triple single-agent using similar therapy. see including a inhibitor to an weekly intermittent encouraged ERK week, were early with Meeting We dosing schedule last responses stage from at the
have to continue pancreatic and make path as responses KO-XXX. of inhibitor such the treat from study to in our with most of patients ERK populations data-driven our on strategy our decisions been the colorectal to support Although confidence in Phase a solid X single-agent date KO-XXX. provide enrolled difficult for to cancer, believe to an foundation more forward move will the forward observation
is KO-XXX, menin-MLL other pipeline menin-mixed a Our potent protein-proteign inhibitor emerging selective or program interaction. leukemia of lineage small-molecule the
subsets support genetically-defined potent fusions with Our NPMX preclinical anti-tumor activity well potential such KO-XXX rearrangements, multiple data as in as as tumors for mutation. for the or MLL
cycles. September, refractory determine dose day X or designed will relapsed In the oral leukemia, open-label in of of clinical once-daily be our we tolerated our to with us XX which trial Phase KO-XXX, in KO-XXX a is administered dose the X first study asset. wholly-owned The giving dosed acute clinical-stage patient Phase oncology as myeloid third maximum in dose-escalation continuous patients
trial, the treatment specific genetic look approach Upon completion we a as to activity and the the cohorts assess of believe KO-XXX mutant. NPMX you. AML, with in of forward are We with such of differentiated to the of represents and sharing subgroups, portion planned updates patients dose-escalation further safety KO-XXX expansion to
Marc discussion I'll the that, With over financial to the now results third for quarter call of our of turn XXXX. for a
